Digistain Analysis

Unit 101, Interchange Business Park, Howard Way, Newport Pagnell, MK16 9PY, United Kingdom

Digistain primarily focuses on the healthcare industry, specifically in the field of oncology, with a particular emphasis on breast cancer treatment through tumor profiling technology.

Digistain operates in the tumor profiling market, specifically focusing on breast cancer risk assessment. Its main competitors include:

1. Oncotype DX: This test analyzes the activity of 21 genes to predict the risk of breast cancer recurrence and the potential benefit of chemotherapy. It is widely used in the U.S. and is known for its established clinical validation.

2. MammaPrint: This genomic test evaluates the activity of 70 genes to determine the risk of recurrence in early-stage breast cancer. It is notable for its ability to provide a binary result (high or low risk) and is used to guide treatment decisions.

3. EndoPredict: This test assesses the expression of 12 genes to predict the risk of distant recurrence in hormone receptor-positive breast cancer. It is particularly advantageous for its ability to provide prognostic information for patients with node-positive disease.

4. Breast Cancer Index: This test analyzes the activity of 7 genes and is used to predict the risk of late recurrence in breast cancer patients. It is unique in its focus on long-term recurrence risk.

Notable Differences and Advantages:

• Technology: Digistain utilizes mid-infrared spectroscopy, which may offer a rapid and cost-effective alternative to traditional genomic tests.
• Personalization: Digistain's approach is designed to provide personalized risk assessments, potentially allowing for more tailored treatment plans.
• Speed: Digistain claims to deliver results faster than some competitors, which can be crucial for timely treatment decisions.